• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Canaccord Genuity initiated coverage on GRAIL with a new price target

    4/21/25 8:38:45 AM ET
    $GRAL
    Medical Specialities
    Health Care
    Get the next $GRAL alert in real time by email
    Canaccord Genuity initiated coverage of GRAIL with a rating of Buy and set a new price target of $32.00
    Get the next $GRAL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRAL

    DatePrice TargetRatingAnalyst
    4/21/2025$32.00Buy
    Canaccord Genuity
    11/27/2024$16.00Equal-Weight
    Morgan Stanley
    11/15/2024Peer Perform
    Wolfe Research
    10/17/2024Neutral
    Guggenheim
    More analyst ratings

    $GRAL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Ding Chun R bought $1,024,698 worth of shares (78,829 units at $13.00) and acquired $879,900 worth of shares (70,000 units at $12.57) (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      10/10/24 7:45:32 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on GRAIL with a new price target

      Canaccord Genuity initiated coverage of GRAIL with a rating of Buy and set a new price target of $32.00

      4/21/25 8:38:45 AM ET
      $GRAL
      Medical Specialities
      Health Care
    • Morgan Stanley initiated coverage on GRAIL with a new price target

      Morgan Stanley initiated coverage of GRAIL with a rating of Equal-Weight and set a new price target of $16.00

      11/27/24 7:29:05 AM ET
      $GRAL
      Medical Specialities
      Health Care
    • Wolfe Research initiated coverage on GRAIL

      Wolfe Research initiated coverage of GRAIL with a rating of Peer Perform

      11/15/24 7:46:11 AM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Leadership Updates

    Live Leadership Updates

    See more
    • GRAIL Appoints Sarah Krevans to Board of Directors

      MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern

      10/21/24 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Wheels Up Announces Gregory Summe to Join Board of Directors

      Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

      8/8/24 8:05:00 AM ET
      $AVTR
      $GRAL
      $NXPI
      $STT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care

    $GRAL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Ofman Joshua J. sold $410,019 worth of shares (9,692 units at $42.30), decreasing direct ownership by 2% to 501,768 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      6/16/25 4:08:27 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Director Summe Gregory L was granted 6,082 shares, increasing direct ownership by 19% to 37,544 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/30/25 7:24:34 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Director Chase William J was granted 6,082 shares, increasing direct ownership by 20% to 35,782 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/30/25 7:23:43 PM ET
      $GRAL
      Medical Specialities
      Health Care